Sarepta Therapeutic (SRPT) Could Be Worth $83-$139/Sh - Analyst

Shares of Sarepta Therapeutic (NASDAQ: SRPT) are surging 132 percent in pre-open trading Wednesday after the company announced that Eteplirsen met it primary endpoint in Duchenne muscular dystrophy (DMD) patients. However, according to one analyst, this may just be the start.

Lazard Capital analyst William Turner said Eteplirsen maximum U.S. rev. opportunity is $750 million and applying 3x-5x market cap/revenue multiple leads to fair value of $83-$139/share.

Despite the positive comments Turner is keeping his Buy rating and price target of $25.00.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $14.99 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• Planet Green halted again, now up 793%
• Apple In Coming Months To Launch Suite Of AI Tools In China-sources - Reuters